[Audio Gap] Quarter and Fiscal Year results. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Mr. Baker, President and CEO.

Good afternoon, and welcome to our conference call for the quarter and fiscal year ended March 31, 2017. And as always, I'm joined by Curt Reynders, our Chief Financial Officer. This call is being webcast live and being recorded. A replay will be available through our website, nve.com. After my opening comments, Curt will present a financial review of the quarter and year. I'll cover business and governance items, then we'll open the call to questions. We issued our press release and filed our annual report on Form 10-K in the past hour following the close of market. Links to documents are available through the SEC's website or our website. Comments we may make that relate to future plans, events, financial results or performance are forward-looking statements that are subject to certain risks and uncertainties, including among others, such factors as our reliance on several large customers for a significant percentage of revenue, uncertainties related to the economic environments in the industries we serve, uncertainties related to future contract, research and development revenue as well as the risk factors listed from time to time in our filings with the SEC, including our just filed annual report. The company undertakes no obligation to update forward-looking statements we may make. We're pleased to report solid results for the past quarter and fiscal year. For the quarter, a 23% increase in product sales, which drove a 12% increase in total revenue and a 16% increase in net income. For the complete fiscal year, product sales increased 7%, total revenue increased 2% and earnings per share was up 6%. Curt will cover the details of our financial results and other highlights from our just filed annual report. Curt?

Thanks, Dan. As Dan said, fourth quarter total revenue increased 12% year-over-year from the fourth quarter of last year due to a 23% increase in product sales, partially offset by a 49% decrease in contract R&D revenue. The product sales increase was due to new customers and increased sales to existing customers and was our third consecutive year-over-year increase. The contract R&D decrease was due to completion of certain contracts. Even though revenues increased, costs and expenses decreased. Gross margin increased to 79% of revenue for the fourth quarter of fiscal 2017 compared to 76% last year, and expenses decreased 1%. Interest income decreased 17% for the fourth quarter due to a decrease in interest-bearing marketable securities. Income before taxes increased 19% to $4.46 million for the quarter compared to $3.75 million for the prior-year quarter. Pretax margin for the quarter was 65%. After taxes, net income for the fourth quarter increased 16% to $3.03 million or $0.62 per diluted share compared to $2.6 million or $0.54 last year. Net margin for the quarter was 44%. For the fiscal year, total revenue increased 2%, driven by a 7% increase in product sales, partially offset by a 35% decrease in contract R&D. We had year-over-year revenue increases in the last 3 quarters of the fiscal year, which more than offset a decrease in the first quarter. For the year, we report revenues in 4 regions: the U.S.; Europe, Middle East and Africa, or EMEA; Asia-Pacific and the rest of the world, which is North and South America, other than the U.S. In the past year, Asia-Pacific was very strong with a 35% revenue increase. This appears to be at least partly because of our more aggressive pricing strategy. The United States increased 10% and 11% for the rest of the world.…

Thanks, Curt. I'll cover new products, contracts, partnerships and fiscal year highlights. As we've said before, our long-term product strategy focuses on bold new technologies such as biosensors. There are 2 thrusts of our near-term growth strategy: first, new and improved products, particularly smaller and lower-powered devices for the Internet of Things; and second, more aggressive pricing to open new markets. We recently introduced 3 new and improved products. First, a low-field angle sensor. Its high- sensitivity means the part can operate with inexpensive magnets and wide mechanical tolerance, which reduces the cost of deployment and opens new applications. Applications include motor controls and Internet of Things and nodes. Like most of our angled sensors, the new part is extremely low power and can run on a button cell or harvested energy. The second recent new product is a new spintronic magnetometer sensor billed as the world's smallest high-performance integrated circuit analog sensor. It's ideal for current-sensing motor controls to improve efficiency. The third new product is the world's smallest high-performance isolated network transceiver. It's 10x faster than our previous products in the so-called quarter-size outline package, or QSOP form factor. The QSOP is 1/4 the size or less of a conventional isolated network transceiver. The new devices are targeted at a high-end industrial Internet of Things, or IIoT. As we have discussed on several of these calls, our pricing strategy is more nuanced than simply cutting prices on existing products. Our strategy is to listen to price-sensitive customers and design products with specifications that meet their needs. That way, we add business and broaden our benefit proposition rather than just cannibalizing existing business. An example of a lower price product introduced in the past quarter is a new coupler called the IL3022. That part is a cost-effective transceiver for…

[Operator Instructions] Your first question comes from the line of Charles Haff of Craig-Hallum.

I had a first question on your last commentary about the private label and the new partner in the automotive market. When you think about the private label business and the resources that you're putting forward there or being asked to put forward, would you envision that the private label business could be a material part of your future here a couple of years from now? And any help you could give us on kind of quantifying that based on the resources that you're putting there today.

Yes, Charles. I think long-term we see that potentially having a material impact on our revenues. In the near term, the next fiscal year, we expect there to be modest revenue. But as we get ramped up with them, we see some excellent potential there.

And as you think about the private label business, what do you think of the financial profile? How does it differ from the financial profile that you have today, either gross margin or operating margin, whichever kind of metrics you want to think about?

Charles, this is Dan. So what's -- what we look at is the private-brand partner has to sell through their distribution channel. So they need additional discounts in order to make a fair profit for everybody. But for us, it means less customer-facing cost. We don't have to support the product sales, we don't have to do the pre-sales support, the post-sales support to the extent that we would if the part were sold under our brand. So we feel that it can be a solid profitability for us. Perhaps not the same kind of gross margins that we can get on products that we sell ourselves, but also there are lower expenses associated with it. But more importantly, what we see as an opportunity to open up broad new markets long-term, as Curt mentioned, that would be very difficult for us to get into by ourselves under our own brand because of the large costs involved in getting into certain markets such as the automotive market. So this company has much of those structures. Those structures already in place. There are incremental costs in order to sell into -- for example, the automotive vertical are much lower than ours would be. So we look at it as a win-win for us, for the partner, and of course for the ultimate customers.

Yes, that makes a lot of strategic sense. I was just trying to understand maybe more of the operating margin. When you strip out the selling expense, do you think that the operating margins on those private label automotive customers would be similar to the operating margins that you have today? Or would they be a little less because you're getting more volume?

They will be a little bit less because of volume. Our gross profit actually will go down. We won't see the same level, 79% of gross margins [ in any one year. ]

Okay. And then I was wondering if you had any update on the project with the National Institutes of Health on hearing aid program? The wireless hearing aids to smartphones? I think you mentioned on the last call that the feasibility study went well. What kind of progress have you made there since the feasibility study?

So we are continuing to work on those types of sensors that are very low-field sensors that can detect fields from magnetic communication modes and we see some excellent potential for that not just in the hearing aid market itself but in a myriad of markets and applications that require extremely sensitive devices. So we saw it as a -- we see it as a research program, but it built some technology and demonstrated feasibility noise figures and sensitivity levels that we've shared with prospective customers. So we see some potential for business there, but also we -- we're pleased with how it provided the platform technology for us that we can extend in a number of directions.

And so do you have any milestones that you expect to be communicating with us in the future on that? Or is most of that internal at this point?

We'll share milestones or accomplishments if we can. The government contract was, as you noted, successfully completed the feasibility study with the National Institutes of Health so there isn't much to report there. If the report becomes public, we can share that. It will be mostly a technical type of report. And then of course, if there are products that results -- or customers, we'd like to be able to share that as well.

Okay. And then in terms of product sales this quarter, your results came in a little bit lower than we were expecting. You mentioned the pricing strategy in Asia and the flexible pricing strategy. How much of a factor do you think price had in this quarterly results? Were you pleased with where your pricing discussions came out? Or did you see more pressure on pricing this quarter?

I think we were pleased with the quarter overall. We expect the product sales will increase this current quarter year-over-year. Of course, that was compared to a relatively weak quarter a year ago. And perhaps even an increase sequentially against a relatively strong quarter we just reported.

Okay. And then I know that some of your contract R&D ends up converting to product sales. Do you have a sense for how much of a leading indicator contract R&D is on next year's product sales? Is it pretty -- a tight relationship? Or is it a fairly loose relationship there?

It's a bit more indirect, Charles, because sometimes the contracts -- we just talked about the contract, for example with NIH that wasn't directly linked to a particular customer. Sometimes we have contracts with potential customers where we're being paid for development and, then in the products that result from that contract, we have a clearer path to selling them. So I'm not sure it would serve as a very good indicator. Our contract R&D is less than it's been as you know in some quarters, but that gives us an opportunity to devote more of those resources to internal R&D. So we've been doing that, and that allows us to develop new products. We talked about 3 of them in the prepared remarks and we've got a number of initiatives underway including the Internet of Things interface, IC. So we can use some of that R&D to develop products that have relatively near-term prospects.

Okay. And then my last question is on the Salmonella project. So it sounds like that's moving along well and on track for August 2017 for the prototype components to be finished. What happens after that? I think that you're still a couple of years away from commercialization, but can you just kind of remind us of what other milestones will be coming up there?

So after the prototype components milestone, which is scheduled for August, we have a fair amount of testing that we're going to be doing. In vitro testing, which would be with -- without Salmonella and then eventually testing with live Salmonella, which we're going to be doing in conjunction with labs at the University of Minnesota, which are set up to handle pathogens. So we are going to be then characterizing the sensitivity of the device at selectivity and other biological parameters. And those are the major tasks that we're going to be doing with the prototype components. We also have some system integration work to turn these components into a commercial system with a user interface, with computers and with the flow and plumbing, fixturing to handle the high volumes that we need for a viable commercial system.

And then in terms of the in vitro testing, how long would you expect that process to take?

Well the -- after the project milestones in August, we have about another year to run, which is variety of tasks including the in vitro testing, then the live bacteria testing. I don't think we have milestones broken out separately, but those are some of the tasks that we have. And then the tasks relating to system development and inter -- user interface as well.

And then just a follow-up there. Do you expect to have commercial discussions during this time? Or is it your sense that any commercial partners would want to wait until you have all the steps done before they would start having more discussions with you?

No, we can have more commercial discussions before we're done, and we're having them now and we've had them in the past. So having actual prototypes and having data gives us a more powerful benefit proposition for prospective customers, but we've had expressions of interest from potential commercial partners, customers for the devices and they're helping us, providing advice and we hope we'll be potential customers for the first systems.

Your next question comes from the line of Jeff Bernstein of Cowen Advisors.

A couple of questions for you. Wanted to see if there was any update on the switch mode power supply business that you're trying to develop?

Yes, so we continue to develop devices for switch mode power supplies. We have customers in that market that take advantage of the extremely small size and low power consumption for high efficiency of our devices. So some of the extensions that we're making for those product lines are higher voltage so these allow for more safety and meeting more rigorous safety standards in both commercial systems and things like medical instrumentation, which have very rigorous standards, as you can imagine. So we've been working on extending our line of what's called reinforced isolation. These are devices that have isolation voltages up to 6 kilovolts, which is an extremely high voltage for very small parts. And then on other fronts, we're working on lower power devices so that we're using less of the power that can be transmitted to -- that can be used by the target devices. There are more and more efficiency standards and power efficiency is becoming almost an obsession in that market. So it's become an obsession of ours and part of our development thrust are to make these devices lower and lower power and then we're making them smaller. So those are the areas that we're working on: making them smaller; more power efficient and more rugged for a higher isolation voltages.

And then I guess doing similar things in the electric vehicle drive train area? Can you say anything about that?

So in that area, we're looking at controller area network transceivers. That's an area where the private brand partnership that we talked about could be important. This is a partner that has a strong presence in the automotive market. And there's a good deal of interest in more networks for hybrid electric vehicles as well as conventional vehicles. And our devices provide a very rugged interface, very low power, which is particularly important for hybrid electric vehicles. You want to manage the power consumption to make the vehicles more efficient, but you don't want to use up power by doing that. So those are -- that's a vertical that's -- that looks very promising for us.

And then can you give an update on the Spin-Torque Microwave Diode Spectrograph for the army I guess it was?

Yes. So that's a program that's on-going and that's a little bit longer term. Spin-torque diodes are an amazing piece of technology. They have the potential to be incredibly fast. Some of the speeds that our guys are talking about are just amazing. And that's of use to the military which is funding this contract, the development contract, but also in other areas, in commercial areas, and things like 5G networks which are going to need much faster electronics and also in our isolator technology where we're looking at the potential to have couplers or isolators that could run at video speeds which are in the gigahertz range or even beyond. So it is a longer term project, but it has some excellent potential for extending the speed of the devices that we make, as well as the potential market in defense.

And can you say anything about developments in the Physical Unclonable Function area?

So the Physical Unclonable Functions are used for anti-tamper and crypto key applications and those have defense applications as you can imagine, but also long term they have commercial applications for things that require enhanced security. And there are a lot of things like that -- credit cards, computer links and we've all heard about, or had experiences with, what happens when information gets compromised. So keeping information secure is a thrust of ours. In the relative near term, we have military and aerospace applications for the technology. And in the longer term, it could be extended to commercial and consumer applications.

Okay. And then, I was just curious, you mentioned the University of Minnesota. I guess in the latest SIA roadmap, they talk about spintronics being one the important ways forward, to kind of get around some of the Moore's Law issues. They cite C-SPIN at the University of Minnesota, as a sort of center of excellence and just wondering what relationship you guys have with them and if you're working on any kind of fundamental SIA roadmap type technologies.

So we have -- I guess I would say we have informal relationships with C-SPIN and with that part of the University of Minnesota and we have formal relationships with other parts of the University of Minnesota. So I mentioned areas that we're cooperating with them on the Salmonella detection and the Department of Agriculture project. So we're cooperating with a couple of areas of the University of Minnesota on those. So we do cooperate with educational institutions where it makes sense and there are number of areas where we do that. We've had several programs -- a very constructive programs with Oregon State University and also we have a relationship with the University of Florida, group at the University of Florida for the biosensor product for work on the aptamers and the nano-beads that are an important part of it. So our folks are very good at cooperating and seeking out industry experts. And I think it's a credit to our researchers that we're a very desirable partner to work with. We're well-respected in the academic circles. And the other area that I'd point out that has been productive for us is that we have a number of researchers who come from the University of Minnesota and from other top universities around the country. So we're one of the companies that I think a lot of researchers in this area would like to work and we're pleased that we've been able to get some of the best and brightest who have graduated from some of those programs either Ph.D.s or postdoctoral fellows. And so it's a great asset to have a university of that caliber in our backyard.

And in terms of the kind of more generally applicable spintronic technology for future IC development, is that something that you guys are pursuing in addition to the [ spintronic ] memory avenue? Or not really? Are you pretty much focused on parts you guys will eventually make?

Well our goal is -- we do some very long-term research as you know, but our goal is to keep an eye on commercialization and commercial applications in everything we do. In some cases, we take a long view, but we're not a university. We're -- our mission is to get technology out of the lab, get it built and get it sold. So in that sense, our focus sometimes is different than universities, but there's some overlap but we have a number of programs underway that are longer term that have some -- just fascinating applications for spintronics. Platform technologies or underlying technologies that could feed a number of devices and commercial applications.

Great. And lastly, could you just give us a [ marked ] update on the medical area? I think you've been strong in cardiac rhythm management and you talked about, I guess, some inventory in that channel that's accumulated over time. Can you just kind of give us an update on what's going on in that area?

So we've talked about and filed a contract that we have -- a supply contract with Abbott, formally St. Jude Medical. We have other medical customers and some we can talk about, some we can't. But with respect to -- you asked specifically about cardiac rhythm management, or CRM. And for -- Abbott's reported that, that's been challenging for them, but they're working on new products. They've said -- St. Jude said that the acquisition by Abbott would expand their global reach, which would help them long-term as a supplier partner. And long-term, the demographics are favorable. Our population is aging. Many of us are going to need CRM devices and they can make a remarkable difference in quality of life. So we feel it's an excellent market long-term. It's been challenging in the relative short-term though.

[Operator Instructions] I'm showing no further questions at this time. I would now like to turn the conference back to Mr. Baker.

Well, thank you. We were pleased to report to a 23% increase in product sales for the quarter, which drove strong earnings growth in the quarter and growth in the fiscal year. We look forward to reporting first quarter results in July and to our Annual Meeting, which is tentatively in early August. Thank you again for participating in the call.

Ladies and gentlemen, this concludes today's conference. Thank you for your participation, and have a wonderful day. You may all disconnect.